Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab after chemoradiotherapy vs chemoradiotherapy alone in limited disease small-cell lung cancer
2024-515755-37-00Phase 2Authorised
- Sponsor
- Norwegian University of Science and Technology
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-515755-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515755-37-00.